Search Results
ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year
TILs and OS in HER2+ early breast cancer: 10-year updated analysis of the ShortHER trial
Study of Targeted Therapy for HER2-Positive Metastatic Breast Cancer
Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancer
ShortHER study: validating the AJCC prognostic stage in HER2+ breast cancer
Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer
Dr. Sramila Aithal Describes the HERceptin Adjuvant (HERA) Trial for HER2-Positive Breast Cancer
Optimizing Therapy in HER2+ Disease with Dr. Hope S. Rugo
New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. Vogel
HER2-Targeted Therapy for HER2 Low-Expressing Breast Cancer
Herceptin—a targeted antibody therapy for breast cancer
#2 HER2+ Triple Positive Breast Cancer (IPT, Herceptin)
